Monogenic causes of cerebral small vessel disease and stroke

Stéphanie Guey1, Hugues Chabriat1

  • 1Translational Centre for Neurovascular Disorders, Hôpital Lariboisière AP-HP, Paris, France; Paris-Cité University, Inserm U1141 NeuroDiderot, Paris, France.

PubMed

Insights

Cerebral small vessel diseases (cSVDs) cause 25% of strokes. Genetic testing is crucial for rare monogenic forms like CADASIL, but many genetic causes remain undiscovered.

Area of Science:

  • Neurology
  • Genetics
  • Vascular Medicine

Background:

  • Cerebral small vessel diseases (cSVDs) contribute significantly to stroke incidence and neurological disability.
  • Monogenic disorders, particularly cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), represent a subset of cSVDs.
  • Clinical presentation and imaging findings can overlap across different Mendelian cSVDs, necessitating comprehensive genetic evaluation.

Purpose of the Study:

  • To highlight the genetic basis of cerebral small vessel diseases (cSVDs).
  • To emphasize the importance of molecular screening in suspected cases of monogenic cSVDs.
  • To discuss the current genetic testing strategies and identify gaps in knowledge regarding the genetic etiology of cSVDs.

Main Methods:

  • Review of current literature on Mendelian forms of cSVDs.
  • Analysis of genetic factors implicated in various cSVD subtypes.
  • Discussion of diagnostic approaches including panel-targeted gene sequencing and exome sequencing.

Main Results:

  • Over a dozen genes are implicated in Mendelian cSVDs, often presenting as autosomal dominant conditions.
  • Specific genes are associated with ischemic stroke (e.g., CADASIL, HTRA1, PADMAL, CARASAL, LAMB1) or intracerebral hemorrhages (e.g., COL4A1/COL4A2, hereditary cerebral amyloid angiopathy).
  • Genetic variants are identified in less than 15% of patients with suspected genetic cerebrovascular disease, indicating a need for further gene discovery.

Conclusions:

  • Early detection of cSVDs with specific clinical and imaging red flags should prompt molecular screening.
  • Simultaneous screening of known genes is the current standard for diagnosing Mendelian cSVDs.
  • A significant proportion of genetic cerebrovascular diseases remain unexplained, underscoring the need to identify novel causative genes.